Clinical trials: Post Discharge
- Condition Post Discharge
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Subjects, Castration Resistant Prostate Cancer (CRPC)
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations.
- Conditions
- Healthy Subjects, Castration Resistant Prostate Cancer (CRPC), Relative Bioavailability, MDV3100
- Trial name
- NCT01911741
- Testing
- MDV3100
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Volunteers
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
This is a phase 1, single-center, randomized, open-label study to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of vamifeport after multiple oral administrations of one immediate-release (IR)…
- Trial name
- NCT06726863
- Testing
- Vamifeport IRF, Vamifeport PR1, Vamifeport PR2
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Schizophrenia
A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy men, and to evaluate the effect of posture on the pharmacokinetics of ER OROS…
- Trial name
- NCT00838669
- Testing
- Extended release OROS paliperidone
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neuropathy;Peripheral
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
- Trial name
- SELECT (NCT05980767)
- Testing
- Temporary Peripheral Nerve Stimulation System
- Where
- 2 sites in Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Epineuron Technologies Inc.
Alzheimer's Disease
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.
- Trial name
- NCT02710188
- Testing
- HTL0009936 modified release, HTL0009936 immediate release
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Healthy Women
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women
The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following single oral doses of three modified-release (MR)…
- Trial name
- NCT02112903
- Testing
- Encapsulated vortioxetine IR tablet, 20 mg, Vortioxetine MR capsule 20 mg (pH 5.5), Vortioxetine MR capsule 20 mg (pH 6.0)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Depressive Disorder
Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects
The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.
- Trial name
- NCT00938184
- Testing
- Paroxetine 12.5 milligrams tablet, Paroxetine 25 milligrams tablet, Paroxetine 50 milligrams tablet
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects
The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg. GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.
- Trial name
- GLA5PR-102 (NCT01638273)
- Testing
- Pregabalin 150mg, Pregabalin 75mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Deep Vein Thrombosis Leg
A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting
This will be a study existing of 4 periods, to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting.
- Trial name
- NCT01347203
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Pain
An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.
The purpose of this study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs after a marathon.
- Trial name
- NCT00240838
- Testing
- acetaminophen extended release caplets
- Volunteers
- 483 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Healthy Participants
Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations
PF-06700841 is a dual Tyrosine kinase 2 (TYK2) Janus kinase 1 (JAK1) inhibitor that is being developed for oral treatment of adult patients with Inflammatory Bowel Disease (IBD).This open-label study will evaluate the…
- Trial name
- NCT03765554
- Testing
- PF-06700841 Immediate release tablets, PF-06700841 Modified release tablets
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with…
- Trial name
- NCT05112939
- Testing
- RPV LA, CAB LA
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study of the Dose Proportionality of Extended Release Paliperidone
The purposes of this study are to evaluate the dose proportionality of 1.5- and 3 mg tablets of paliperidone ER, to document the pharmacokinetics of a 1.5 mg dose of paliperidone ER, and to assess the safety and tolerability of…
- Trial name
- NCT00791167
- Testing
- Paliperidone ER
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetic Neuropathies, Diabetes Mellitus
Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults
A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Food Effect, Single-Dose Proportionality, and Multiple-Dose Pharmacokinetic Comparison with Melogabalin Besilate Tablets after Single and Multiple Oral…
- Trial name
- NCT06846567
- Testing
- BM2216 Extended-Release tablets（5.5mg）, Mirogabalin Besilate Tablets, BM2216 Extended-Release Tablets(11mg)
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Zhejiang Anglikang Pharmaceutical Co., Ltd.
Depressive Disorder
Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects
The study was designed to describe the relationship between dose and pharmacokinetic parameters of paroxetine over the range of proposed dosage strengths of the paroxetine CR tablet (12.5 to 37.5 mg) as well as safety profile
- Trial name
- NCT00406003
- Testing
- Paroxetine controlled release tablet
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
- Trial name
- NCT00964262
- Testing
- SR Exenatide (PT302)
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Peptron, Inc.
Opioid-Related Disorders, Pain, Acute
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
This clinical trial is being conducted to compare concentrations of hydrocodone and acetaminophen in the blood after administration of different amounts of tablets of a new and a marketed tablet formulation in healthy adults.
- Conditions
- Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
- Trial name
- NCT03137030
- Testing
- GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Healthy
AZD0837 Extended Release (ER) Japan Study
This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.
- Trial name
- ER J ph I (NCT00904800)
- Testing
- AZD0837
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
The purpose of this study is to determine brain penetration of single oral doses of TAK-041 and its effects on amphetamine-induced dopamine release in the Central Nervous System (CNS).
- Trial name
- NCT02959892
- Testing
- Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Schizophrenia
A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone
The purpose of this study is to characterize the pharmacokinetics of paliperidone in plasma and urine after intravenous (i.v.) administration of the racemate, administration of the immediate-release (IR) racemate oral solution…
- Trial name
- NCT00796276
- Testing
- IR OROS paliperidone and ER OROS paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.